How Thelansis Supported a Mid-Sized Biopharma Company in Out-Licensing Their Novel IPF Asset
Introduction: During 2024, a mid-sized biopharma company from the European region was developing a novel systematic therapy for the treatment of IPF, seeking an evidence-backed structured partnership ...
From Evidence to Impact: How Thelansis Accelerated a Rare Disease Submission
Introduction: In recent years, the healthcare landscape has evolved toward an evidence-based, patient-centric architecture. Although conventional clinical trials remain the gold standard, they do not ...